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 Background A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of second-
ary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.
 Methods A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant 
colorectal cancer cells. The candidate gene SRBC was validated by single-locus DNA methylation and expression 
techniques. Transfection and short hairpin experiments were used to assess oxaliplatin sensitivity. Progression-
free survival (PFS) and overall survival (OS) in metastasic colorectal cancer patients were explored with Kaplan–
Meier and Cox regression analyses. All statistical tests were two-sided.
 Results We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation–associated inac-
tivation of the BRCA1 interactor SRBC gene. SRBC overexpression or depletion gives rise to sensitivity or resist-
ance to oxaliplatin, respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort 
of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% 
confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which 
metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01). In a validation cohort of 
unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with 
shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045).
 Conclusions These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker 
for oxaliplatin resistance in colorectal cancer.
  J Natl Cancer Inst 
Colorectal cancer (CRC) is the second most common cause of 
cancer death in the western world (1). In metastatic CRC, poly-
chemotherapy based on fluoropyrimidines plus oxaliplatin or 
irinotecan, combined with biological agents such as cetuximab 
and panitumumab, is the gold-standard treatment (2). Oxaliplatin 
forms intrastrand adducts that disrupt DNA replication and tran-
scription (3,4). DNA damage induced by oxaliplatin is repaired in 
part by the nucleotide excision repair pathway (5), but the DNA 
double-strand breaks induced by the drug are also repaired by the 
BRCA1 complex (6–8). In this regard, epigenetic inactivation of the 
BRCA1 gene by promoter CpG island methylation has been associ-
ated with increased sensitivity to cisplatin and carboplatin in breast 
and ovarian cancer (9,10).
Genes critical to colorectal tumor biology are frequently inacti-
vated by hypermethylation of the CpG dinucleotides located in their 
5’-CpG island regulatory regions (11–13). We wondered whether 
this epigenetic alteration was involved in the resistance to oxalipl-
atin in CRC, where treatment failure due to primary or acquired 
resistance remains a major obstacle to the management of the dis-
ease. Herein, we demonstrate that the epigenetic inactivation of the 
BRCA1 interactor SRBC gene by promoter CpG island hypermeth-
ylation is associated with poor outcome upon oxaliplatin treatment.
Methods
Cell Lines
LoVo parental cell line (LoVo-S) and its derived 10-fold oxali-
platin-resistant cells (LoVo-R)(14) were cultured at 37ºC in an 
atmosphere of 5% (v/v) carbon dioxide in Dulbecco’s Modified 
Eagle’s Medium/Ham’s Nutrient Mixture F12 (DMEM-HAM’s 
F12) medium supplemented with 20% (w/v) fetal bovine serum, 
100 U penicillin, and 100 µg/L streptomycin (Invitrogen, Carlsbad, 
CA).The HCT-116, SW48, SW480, SW620, RKO, Co115, and 
HCT-15 CRC cell lines were obtained from the American Type 
Culture Collection (Manassas, VA). Cell lines were authenticated 
by short tandem repeat profiling.
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Determination of Drug Resistance
Oxaliplatin (5 mg/mL) and 5-fluorouracil (50 mg/mL) were 
obtained from TEVA (North Wales, PA) and Accord Healthcare 
SLU (Barcelona, Spain), respectively. Cell viability was deter-
mined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide (MTT) assay. Briefly, 1 × 103 cells were 
plated onto 96-well plates. Cells were treated for 120 hours with 
different drug concentrations (oxaliplatin: 0–250 µM; 5-fluoro-
uracil: 0–35  µM). MTT was added at a final concentration of 
0.1%. After 2.5 hours of incubation (37 ºC; 5% carbon dioxide), 
the MTT metabolic product formazan was dissolved in dime-
thyl sulfoxide (DMSO), and absorbance was measured at 570 nm. 
Prism Software (La Jolla, CA) was used to calculate the drugs’ 
half-maximal inhibitory concentration (IC50).
DNA Methylation Analyses
DNA was subjected to bisulfite using EZ DNA methylation kit 
(Zymo Research, Orange, CA) as previously described (15). To per-
form the genome-wide DNA methylation profiling we used the 
Illumina Infinium HumanMethylation27 BeadChip (Illumina, San 
Diego, CA) microarray following the manufacturer’s instructions 
(15).The Infinium assay quantifies DNA methylation levels at spe-
cific cytosine residues adjacent to guanine residues (CpG loci), by 
calculating the ratio (β value) of intensities between locus-specific 
methylated and unmethylated bead-bound probes. The β value is 
a continuous variable, ranging from 0 (unmethylated) to 1 (fully 
methylated). This microarray assesses the DNA methylation level 
of 27 578 CpG sites located at the promoter regions of 14  495 
protein-coding genes. DNAs were processed on the same microar-
ray to avoid batch effects. The array was scanned by a Bead Array 
Reader (Illumina), and intensity data were analyzed using Genome 
Studio software (version 2011.1; Illumina). Further details are 
described in the Supplementary Methods (available online). The 
data is freely avalilable at GeneExpressionOmnibus (http://www.
ncbi.nlm.nih.gov/geo/) under GEO accession code GSE44446.
We established SRBC CpG island methylation status using 
three different polymerase chain reaction (PCR)–based techniques: 
bisulfite genomic sequencing of multiple clones, methylation-specific 
PCR, and pyrosequencing. Further technical details are described 
in the Supplementary Methods (available online).The used primer 
sequences are shown in Supplementary Table 1 (available online).
mRNA and Protein Expression Analyses
mRNA extraction, cDNA synthesis, conventional and quantitative 
real-time PCR (RT-PCR) using Hs00376942_m1Taqman Gene 
Expression assay (Applied Biosystems. Madrid, Spain) were per-
formed as previously described (16). Primer sequences are shown 
in Supplementary Table  1 (available online). Anti-SRBC (1/1000) 
from Cell Signaling and anti-β-actin-HRP antibody (1/20 000) from 
Sigma (St. Louis, MO) were used to develop the western blot analysis.
SRBC Transfection and Depletion Experiments
Human short hairpin RNAs and cDNA plasmids for SRBC were 
obtained from Origene (Rockville, MD). After Escherichia coli trans-
formation, we proceeded to plasmid DNA purification. Forty-eight 
hours after electroporation, cells transfected with short hairpin 
RNAs (TR317747; Origene) were grown in medium containing 
0.8 or 0.6  µg/mL of puromycin (LoVo-S and HCT-116). Cells 
transfected with SRBC cDNA (SC320781; Origene) were grown 
with DMEM containing 0.8 or 0.6 mg/mL of geneticin (G418, 
LoVo-R, and HCT-15) to perform clonal selection. Once selected, 
clones were picked, grown, and tested by Western blot.
Patients
In our study, we analyzed two independent cohorts of white, stage IV 
CRC patients (17). In the discovery set, 131 metastatic CRC primary 
tumors that received oxaliplatin plus fluoropirimidines–based therapy 
were retrospectively included. Formalin-fixed paraffin-embedded 
tumors obtained by surgical resection came from three different hos-
pitals (ICO-Hospitalet, ICO-Badalona, and Niguarda Ca’ Granda). 
Clinical features of the patients are showed in Table  1. From this 
cohort, 65 patients could undergo surgery to remove metastases. 
After neoadjuvant regimen, 34 could be operated, and 31 received 
palliative regimen. The rest of the patients (n = 66) showed unresect-
able metastases and directly underwent palliative regimen. The great-
est time of follow-up of this group was near 10 years. The validation 
cohort consisted of 58 stage IV CRC patients from the Hospital Vall 
d’Hebron with a follow-up of nearly 3 years (Table 1). According to 
discovery set results, we selected patients with unresectable metas-
tases who received oxaliplatin plus fluoropirimidines–based therapy 
in a neoadjuvant (n = 20) or palliative regimen (n = 38). The distri-
bution of patients according to the different clinical features was 
similar in both cohorts. Signed informed consent was obtained from 
each patient, and the Clinical Research Ethical Committee from 
ICO-Hospitalet provided approval for the study. DNA from all case 
patients was obtained from formalin-fixed paraffin-embedded tissue 
sections (10 µm) by xilol deparafination and digestion by proteinase 
K (Qiagen, Manchester, UK). Tumor specimens were composed of 
at least 70% carcinoma cells. DNA extraction was performed using 
a commercial kit (Qiagen) following the manufacturer’s instructions.
Statistical Analysis
In both independent cohorts we analyzed SRBC promoter methyla-
tion status and its association with response rate, progression-free 
survival (PFS), and overall survival (OS). The associations between 
categorical variables were assessed by χ2 tests or Fisher exact test 
whenever required. Kaplan–Meier plots and log-rank test were used 
to estimate PFS and OS. The association between epigenetic vari-
ant and clinical parameters with PFS and OS was assessed through 
univariate and multivariable Cox proportional hazards regression 
models. The proportional hazards assumption for a Cox regression 
model was tested under R statistical software (Boston, MA) (cox.
zph function). Statistical analysis was performed by using SPSS for 
Windows, (Armonk, NY) and P values less than .05 were considered 
statistically significant. All statistical tests were two-sided.
results
Identification of Epigenetics Changes Associated 
With Oxaliplatin Resistance Using a DNA Methylation 
Microarray
To address in an unbiased manner whether epigenetic changes 
can be associated with oxaliplatin resistance, we adopted a whole 
genomic approach by comparing the DNA methylation status of 
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27 000 CpG sites (15) in an oxaliplatin-sensitive CRC cell line 
(LoVo-S) and an oxaliplatin-resistant clone (LoVo-R) that we 
derived by exposure to increasing concentrations of the drug (14).
This approach yielded only three differentially methyl-
ated target genes: SRBC (protein kinase C delta binding pro-
tein), FAM111A (family with sequence similarity 111, member 
A) and FAM84A (family with sequence similarity 84, member A) 
(Supplementary Figure 1A, available online). The most noteworthy 
gene with the highest difference in DNA methylation was SRBC; 
thus, it was the logical option to pursue. However, we also stud-
ied initially the other two genes. For FAM111A, bisulfite genomic 
sequencing of multiple clones showed that indeed the CpG site 
included in the DNA methylation microarray was distinctly meth-
ylated in LoVo-S and LoVo-R cells; however, the remaining sites of 
the CpG island were unchanged (Supplementary Figure 1B, availa-
ble online). Thus, we excluded this gene from further experiments. 
For FAM84A, bisulfite genomic sequencing confirmed the differ-
ential methylation of the CpG island, but both conventional and 
quantitative RT-PCR did not show any difference in gene expres-
sion (Supplementary Figure 1, D and E, available online). Thus, we 
also excluded this second gene from further analyses. For the main 
target gene, SRBC, the DNA methylation microarray data showed 
that it had a CpG site located in its 5’-CpG island (−155 base-pair 
position) that was hypermethylated in LoVo-R but unmethylated in 
LoVo-S (Supplementary Figure 1A, available online). Interestingly, 
SRBC CpG island methylation-associated silencing has already 
been found in cancer (18,19), including colorectal tumors (20). 
From a functional standpoint, it is biologically plausible that SRBC 
is responsible for the different sensitivity to oxaliplatin because its 
protein interacts with the product of the BRCA1 gene (18), which 
is widely accepted as being a mediator of response to DNA damage 
induced by platinum compounds (21).
To further demonstrate the presence of SRBC 5’-CpG island 
methylation in resistant cells, we undertook bisulfite genomic 
sequencing analyses. We found CpG island hypermethylation 
in LoVo-R but mostly an unmethylated CpG island in LoVo-S 
(Figure  1A). Importantly, SRBC expression was diminished 
in LoVo-R, showing CpG island methylation, whereas it was 
expressed in the unmethylated LoVo-S at the mRNA and protein 
levels (Figure 1B). SRBC re-expression was observed upon treat-
ment with the DNA demethylating agent 5-aza-2’-deoxycytidine 
in LoVo-R cells (Figure 1B).
SRBC Epigenetic Inactivation and Oxaliplatin Resistance
We next sought to demonstrate that the epigenetic inactivation 
of this gene functionally contributed to oxaliplatin resistance. We 
restored the expression of SRBC in LoVo-R by stably transfecting 
an exogenous expression vector (Figure 1C). Upon SRBC transfec-
tion, the cells proved to be statistically significantly more sensitive 
to the antiproliferative activity of oxaliplatin measured by the MTT 
Figure  1. Epigenetic inactivation of SRBC is associated with resist-
ance to oxaliplatin in colon cancer cells. A) Bisulfite genomic sequenc-
ing of eight individual clones in the SRBC promoter CpG island was 
used to determine DNA methylation status. Presence of a methylated 
or unmethylated cytosine is indicated by a black or white square, 
respectively. Black arrows indicate the position of the bisulfite genomic 
sequencing primers. B) SRBC expression determined by semiquanti-
tative real-time polymerase chain reaction analyses (left) and Western 
blot (right). GAPDH and β-actin were used as controls, respectively. 
The oxaliplatin-resistant cell line (LoVo-R) features a hypermethylated 
CpG island that is associated with the downregulation of the SRBC 
transcript and protein, in comparison with the SRBC-unmethylated 
and expressing oxaliplatin-sensitive cells (LoVO-S). Pharmacological 
treatment with the DNA demethylating agent 5-aza-2’-deoxycytidine 
(5-AZA) restores SRBC expression. C) Western blot showing the in vitro 
enhancement (transfection in LoVo-R, left) or depletion (short hairpin 
[sh] RNA approach in LoVo-S, right) of the SRBC protein. D) Cell viability 
determined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazo-
lium bromide assay upon use of oxaliplatin. External intervention by 
inducing SRBC overexpression (in LoVo-R cells) or depletion (in LoVo-S 
cells) gives rise to sensitivity or resistance to oxaliplatin, respectively 
(left panels). 5-Fluorouracil sensitivity is not dependent on SRBC activ-
ity (right panels). The corresponding half-maximal inhibitory concentra-
tion (IC50) values are also shown. SD = standard deviation.
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assay (Figure  1D) than were the empty vector-transfected cells 
(LoVo-R + SRBC 1 and 2: P =  .02 and P < .001, respectively). In 
sharp contrast, we observed that SRBC stable downregulation by 
the short hairpin RNA approach in SRBC-expressing and unmeth-
ylated sensitive cells (LoVo-S) (Figure 1C) had the opposite effect: a 
considerable enhancement of the resistance to the antiproliferative 
effect mediated by oxaliplatin (Figure 1D) (LoVo-S short hairpin 
SRBC A and B: P = .04 and P < .001, respectively). The observed 
effects were specific for oxaliplatin because the in vitro depletion 
or enhancement of SRBC activity did not change the sensitivity to 
5-fluorouracil (Figure 1D), other drug commonly used in CRC.
We extended our study to seven additional CRC cell lines 
(Co115, HCT-15, HCT-116, SW48, SW480, SW620, and RKO), 
in which we found SRBC promoter CpG island hypermeth-
ylation (Figure 2A) and the associated loss of expression only in 
HCT-15 cells (Figure 2B). Interestingly, these cells were the only 
ones showing resistance to oxaliplatin (IC50 ± standard devia-
tion  =  3.81 ± 0.18 µM); the remaining cells were sensitive to the 
drug (Figure 2C) (IC50 values ranging from 0.30 to 0.83 µM). As 
we did with LoVo-S and LoVo-R, we also sought to demonstrate 
that SRBC epigenetic inactivation functionally contributed to 
oxaliplatin resistance in these cells. We restored the expression of 
SRBC in the resistant cell line HCT-15 by stably transfecting an 
exogenous expression vector (Supplementary Figure 2A, available 
online). Upon SRBC transfection, the cells proved to be statisti-
cally significantly more sensitive to the antiproliferative activity of 
oxaliplatin (HCT15 + SRBC: P = .02) (Supplementary Figure 2B, 
available online). The opposite effect was observed with SRBC 
stable downregulation using the short hairpin RNA approach in 
SRBC-expressing and unmethylated sensitive cells (HCT-116): a 
noteworthy increase in the resistance to the antiproliferative effect 
mediated by oxaliplatin was found (Supplementary Figure  2B, 
available online) (HCT-116 short hairpin SRBC A and B: P < .001). 
The described effects were specific for oxaliplatin because the in 
vitro depletion or enhancement of SRBC activity did not change 
the sensitivity to 5-fluorouracil (Supplementary Figure 2B, avail-
able online). Western blot analyses showed that the level of expres-
sion of the SRBC protein in the transfected clones was similar to 
Figure  2. Epigenetic inactivation of SRBC is associated with oxaliplatin 
resistance in colorectal cancer cell lines. A) Bisulfite genomic sequencing 
of eight individual clones in the SRBC promoter CpG island was used to 
determine DNA methylation status. Presence of a methylated or unmethyl-
ated cytosine is indicated by a black or white square, respectively. Black 
arrows indicate the position of the bisulfite genomic sequencing primers. 
HCT-15 cells are the only cells that present SRBC promoter CpG island 
hypermethylation. Normal colon mucosa samples (NC1 and NC2) are 
unmethylated. B) Western blot analyses for SRBC expression show that the 
hypermethylated CpG island in HCT-15 cells is associated with loss of pro-
tein in comparison with the remaining SRBC-unmethylated and -express-
ing colon cancer cell lines. C) Half-maximal inhibitory concentration (IC50) 
values, determined by the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide assay assay, upon use of oxaliplatin in the panel 
of colon cancer cell lines. All the studied cells are sensitive to oxaliplatin 
except the SRBC-hypermethylated and -silenced HCT-15 cell line.
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that observed in unmethylated CRC cell lines (Supplementary 
Figure 2A, available online).
SRBC Hypermethylation and PFS in Oxaliplatin-Treated 
Cases of Unresectable Colorectal Cancer
Given these in vitro findings that colon cancer cells with SRBC 
methylation-associated silencing were resistant to oxaliplatin, we 
wondered whether the same effect could be observed in clinical 
samples. The study of a first clinical cohort of 131 stage IV colorec-
tal adenocarcinoma patients (termed “discovery cohort”) (Table 1), 
all of whom were treated with oxaliplatin in combination with a 
fluoropyrimidine, showed SRBC methylation in 29.8% (n  =  39 
of 131) of the case patients analyzed by both methylation-specific 
PCR and pyrosequencing analyses (Figure  3A; Supplementary 
Figure  3, available online). The described occurrence of SRBC 
hypermethylation in colorectal tumors was identical to the one 
available in the The Cancer Genome Atlas datasets (30.2%; n = 70 
of 232). Considering the whole population of studied advanced 
CRC case patients (n = 131), we observed that SRBC hypermethyl-
ation was associated with PFS (HR = 1.83; 95% confidence interval 
[CI] = 1.15 to 2.92; log-rank P = .01) (Figure 3B). For the 105 case 
patients for whom OS information was available, SRBC hyper-
methylation was not associated with this variable (Figure 3C).
According to Cox regression multivariable test, surgery of metas-
tases showed to be an independent PFS (HR = 0.43; 95% CI = 0.24 
to 0.76; log-rank P  =  .004) and OS (HR = 0.16; 95% CI = 0.04 
to 0.52; log-rank P  =  .003) prognostic factor (Supplementary 
Figure 4, available online). Taking this into account, our cohort was 
stratified in relation to this clinical feature and was divided into 
two groups: patients that underwent metastases resection (n = 34) 
and patients with unresectable metastases (n  =  97). Subdividing 
the discovery cohort into these resectable or unresectable groups, 
SRBC hypermethylation did not have any predictive effect in PFS 
and OS for those case patients that received oxaliplatin as neoadju-
vant therapy followed by the successful resection of the metastases 
(Supplementary Figure 5, available online).
However, the scenario was completely different in the context 
of patients with colorectal adenocarcinomas with unresectable 
metastases who received oxaliplatin as neoadjuvant therapy and 
were subsequently not eligible for surgery (n = 31) or patients with 
tumors that were originally classified as unresectable and were 
given oxaliplatin as palliative chemotherapy (n  =  66). For these 
97 oxaliplatin-treated advanced CRC case patients with unresect-
able metastases, SRBC CpG island hypermethylation was statisti-
cally significantly associated with shorter PFS (HR  =  1.96; 95% 
CI  =  1.13 to 3.40; log-rank P  =  .01) (Figure  3D). In this set of 
case patients, for whom OS data were available for 79 patients, we 
also observed that SRBC hypermethylation was statistically signifi-
cantly associated with shorter OS (HR = 2.01; 95% CI = 1.13 to 
3.40; log-rank P =  .04). These interesting results prompted us to 
study the SRBC methylation status in a second independent set of 
CRC patients with unresectable metastasis who also received oxali-
platin-based therapy (n = 58) (Table 1). In this validation cohort, 
we confirmed that the presence of SRBC hypermethylation was 
associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; 
log-rank P  =  .045) (Figure  4). Thus, the clinical data are similar 
to the results from the aforementioned cell cultures that suggest 
increased chemoresistance of SRBC hypermethylated colorectal 
tumors to oxaliplatin treatment.
Discussion
The preexistence (primary resistance) or the de novo development 
(secondary resistance) of cellular mechanisms to escape the anti-
tumoral effects mediated by the anticancer compounds probably 
involve a wide repertoire of genetic and epigenetic (22) events. 
From a genetics perspective in CRC, it has been described that 
the presence of KRAS mutations and gene amplification of the 
EGFR or MET genesis is associated with resistance to overall 
anti-EGFR therapies (23,24,25). However, from an epigenetics 
perspective, very little is known. In spite of promising pharmacoe-
pigenetics biomarkers, such as the example of MGMT hypermeth-
ylation and good response to temozolamide in gliomas (26), have 
been described for other tumor types, the examples in colorectal 
neoplasms are scarce, even more so if we just focus on resistance 
biomarkers. Herein, we provide an example to help fill this niche 
by showing that SRBC hypermethylation predicts resistance to 
the commonly used agent oxaliplatin in metastatic CRC, a disease 
stage that represents the second most common cause of death from 
cancer (1).
A role of SRBC in mediating different sensitivity to oxaliplatin 
can be clearly justified by its protein interaction with the product of 
the BRCA1 gene (18). The BRCA1 protein exerts an important role 
in DNA double-strand break repair through homologous recom-
bination 2, so its deficiencies can impair the capacity of cancer cells 
to repair DNA cross-links caused by chemotherapy drugs such 
as platinum derivatives (3–7).Two independent studies reported 
greater primary chemotherapy sensitivity to platinum-based chem-
otherapy agents in patients with ovarian cancer who were carriers 
of BRCA1 germline mutations (5,6). These observations have also 
been extended to BRCA1 epigenetic silencing in sporadic breast 
and ovarian tumors, where it also predicts a good response to cispl-
atin and carboplatin (9,10,27). However, the biology of mammary 
tumors is very different from colorectal malignancies, and in all 
cases of colon cancer, the BRCA1 promoter has always been found 
in an unmethylated status (28–30). Interestingly, in addition to its 
BRCA1-related roles, SRBC might have other functions related to 
the observed chemoresistance phenotype, such as its interaction 
with caveolin 1, which may putatively affect intracellular vesicle 
traffic of the drug (31).
It is worth mentioning two possible avenues of further research. 
First, there is the possibility to detect SRBC hypermethylation by 
sensitive user-friendly techniques, such as methylation-specific 
PCR and pyrosequencing, which could be useful in the clinical 
setting. Instead of always requiring the use of the surgical tumor 
sample, stool or serum/plasma DNA could be useful alterna-
tive biological materials to predict oxaliplatin resistance in CRC 
patients. In this regard, DNA methylation changes are also ame-
nable for the development of new powerful molecular techniques, 
such as those recently referred to as “liquid biopsies” (32). Second, 
our observation that sensitivity to oxaliplatin can be restored by 
the re-expression of the SRBC gene could represent a revival of 
the DNA demethylating agents in the therapy of solid tumors. 
With little therapeutic options against metastatic CRC once it has 
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Figure 3. SRBC promoter hypermethylation occurs in primary tumors 
from colorectal cancer patients, where it predicts shorter progression-
free survival (PFS) in oxaliplatin-treated case patients. A) Analysis by 
methylation-specific polymerase chain reaction (MSP) of the promoter 
region of SRBC in primary colorectal tumors. The presence of a vis-
ible polymerase chain reaction product in lanes marked U indicates 
unmethylated SRBC sequences; the presence of a product in lanes 
marked M indicates methylated sequences. In vitro methylated DNA 
(IVD) was used as a positive control for methylated SRBC sequences. 
DNA from normal lymphocytes (NL) was used as a negative control 
for methylated SRBC sequences. MSP of SRBC in five colon cancer 
patients demonstrates SRBC promoter hypermethylation in tumors 1, 
3, and 5. B) Kaplan–Meier analysis of PFS among the whole popula-
tion of advanced colorectal cancer cases by SRBC methylation status. 
Numbers of events (progression) are shown from 24 to 240 months in 
unmethylated (U) and methylated (M) groups. C) Kaplan–Meier analy-
sis of overall survival (OS) among the whole population of advanced 
colorectal cancer cases by SRBC methylation status. Numbers of 
events (exitus) are shown from 6 to 36 months in unmethylated (U) 
and methylated (M) groups. D) Kaplan–Meier analysis of PFS among 
the oxaliplatin-treated advanced colorectal cancer case patients with 
unresectable metastases by SRBC methylation status. Numbers of 
events are shown from 24 to 240  months in unmethylated (U) and 
methylated (M) groups. E) Kaplan–Meier analysis of OS among the 
oxaliplatin-treated advanced colorectal cancer case patients with unre-
sectable metastases by SRBC methylation status. Numbers of events 
are shown from 6 to 36 months in unmethylated (U) and methylated 
(M) groups.
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become insensitive to oxaliplatin, DNA methylation inhibitors, 
such as 5-azacytidine and 5-aza-2′-deoxycytidine, could be used to 
resensitize these tumors to the oxaliplatin therapy. This idea has 
been recently explored in non–small cell lung carcinoma patients 
who had reached the last line of chemotherapy. The subsequent 
administration of 5-azacytidine was able to rescue previous chemo-
sensitivity (33).
Limitations of our study to be addressed in further research 
include the lack of knowledge about the molecular mechanisms 
linking SRBC activity and DNA damage repair triggered by oxali-
platin, the use of nonquantitative DNA methylation assays that will 
require transformation to quantitative DNA methylation tests to 
get specific cut offs for a future clinical application, and the exten-
sion of our CRC patient data source to stage II and III tumors and 
samples from other geographical origins.
In conclusion, we have demonstrated that DNA methyla-
tion–associated silencing of the BRCA1 interactor gene SRBC 
is associated with the acquisition of chemoresistance to the 
DNA damaging agent oxaliplatin in CRC both in vitro and in 
vivo. The validation of SRBC hypermethylation as a predictive 
marker will require further prospective studies. If successful, 
clinical trials would also be necessary to develop strategies to 
overcome or prevent the development of SRBC-mediated epi-
genetic resistance.
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